Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications
Author:
Affiliation:
1. Simcoe Muskoka Regional Cancer ProgramRoyal Victoria Regional Health Centre Barrie Ontario Canada
2. Provincial Drug Reimbursement ProgramsCancer Care Ontario Toronto Ontario Canada
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32985
Reference27 articles.
1. Monoclonal Antibodies for B-Cell Lymphomas: Rituximab and Beyond
2. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
3. Aggressive lymphoma: improving treatment outcome with rituximab
4. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
5. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Montelukast as a Rescue and Premedication for Rituximab Infusion Reactions;The Journal of Rheumatology;2024-06-15
2. The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial;JMIR Research Protocols;2024-02-22
3. Characteristics and predictors of infusion-related reactions to rituximab in patients with B-cell non-Hodgkin lymphoma;Journal of Chemotherapy;2023-10-20
4. Comparison of Adverse Events between Diphenhydramine and Levocetirizine Pretreatment in Multiple Myeloma Patients Treated with Subcutaneous Daratumumab;Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences);2023-08-10
5. Bendamustine and rituximab is well‐tolerated and efficient in the treatment of indolent non‐Hodgkin ' s lymphoma and mantle cell lymphoma in elderly: A single center observational study;International Journal of Cancer;2022-12-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3